1298101-47-9

Usage

Uses

Used in Organic Synthesis:
Tert-butyl (1S,3R)-3-aminocyclohexylcarbamate is used as a building block in organic synthesis for the preparation of various pharmaceuticals and biologically active compounds. Its unique structure and functional groups contribute to the creation of diverse molecular scaffolds and pharmacologically relevant molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl (1S,3R)-3-aminocyclohexylcarbamate is utilized as a key intermediate for the synthesis of pharmaceuticals. Its properties and potential applications make it an important target for research and development, as it can be incorporated into the design and synthesis of new drugs with improved therapeutic effects.
Used in Pharmaceutical Industry:
Tert-butyl (1S,3R)-3-aminocyclohexylcarbamate is used as a reagent in the pharmaceutical industry for the development of new drugs and therapeutic agents. Its versatility and unique structural features enable the synthesis of a wide range of biologically active compounds, contributing to the advancement of medicinal chemistry and drug discovery.

Upstream product

• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 1261225-48-2 [3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 222530-39-4 (1R,3S)-3-(tert-butoxycarbonylamino)aminocyclohexanecarboxylic acid 
• 1259278-12-0 benzyl N-[(1S,3R)-3-aminocyclohexyl]carbamate 
• 1259278-11-9 benzyl N-[(1S,3R)-3-carbamoylcyclohexyl]carbamate 
• 1259278-09-5 ethyl (1R,3S)-3-benzyloxycarbonylaminocyclohexane-1-carboxylate 
• 1261225-49-3 [3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 227783-08-6 (1S,3R)-3-ethoxycarbonylcyclohexane-1-carboxylic acid 
• 53084-60-9 ethyl (1R,3S)-3-aminocyclohexanecarboxylate 

Relevant academic research and scientific papers

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

CYCLOALKANE-1,3-DIAMINE DERIVATIVE

The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.

HETEROCYCLIC INDOLES FOR USE IN INFLUENZA VIRUS INFECTION

The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Heterocycle derivatives and drugs

There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a compound represented by the following formula: or a salt thereof. In the formula, X and Y are same or different and each represents a nitrogen atom or CH; R1 represents a hydrogen atom or alkyl and the like; A1 and A2 are same or different and each represents a single bond or a divalent aliphatic hydrocarbon group; Q represents a single bond, cycloalkylene group, phenylene group or divalent heterocyclic group; R2A, R2B, R2C and R2D are same or different and each represents a hydrogen atom, alkyl or phenyl; E represents a ethenylene group or —NRCO— (in which R is hydrogen or alkyl) and the like; R3 represents a phenyl group or a heterocyclic group; R4 and R5 are same or different and each represents a hydrogen atom, alkyl, alkoxy, aralkyloxy, halogen, nitro, hydroxy, alkoxycarbonyl, —NR6R7 (in which R6 and R7 are same or different and each represents a hydrogen atom or alkyl) and the like.